{"slug":"vip-neuropathy","verification":{"valid":true,"entries":2,"head":"814970a7d9c062b74b764263f77fd08e56991aaaa42527bfcb52ddbba6715174"},"energy":{"passes":2,"tokens_in":32881,"tokens_out":3494,"tokens_total":36375,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"814970a7d9c062b74b764263f77fd08e56991aaaa42527bfcb52ddbba6715174"},"provenance":[{"ts":"2026-06-29T22:27:49.680Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Neuropathy\nSlug: vip-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_s","response":"{\n  \"slug\": \"vip-neuropathy\",\n  \"title\": \"VIP for Neuropathy: Evidence-Graded Look at Immune and Autonomic Layers\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive loss of nerve structure and function. Peripheral nerves lose myelin, axons degenerate, and inflammation persists in the nerve environment. Schwann cells that support myelin fail to repair damage quickly enough. Immune cells like macrophages stay activated and release cytokines that slow recovery. Autonomic nerves that control blood flow and organ signals can also show altered peptide expression. When repair pathways lag behind ongoing breakdown, symptoms continue. VIP is discussed in this context because studies examine its effects on immune balance and nerve-support cells rather than direct symptom masking.\\n\\n## Why VIP might help you\\n\\nIf immune activation and autonomic signaling form part of your neuropathy picture, VIP is examined for its potential effects on those layers. The logic runs like this: injured nerves up-regulate VIP expression; VIP acts on receptors present on Schwann cells and immune cells in the nerve stump; those actions shift cytokine profiles toward less inflammation and support myelin-related gene expression. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nStep 1: Nerve injury triggers local VIP increase in animal models. Step 2: VIP binds VPAC receptors on Schwann cells. Step 3: This binding correlates with higher expression of myelin genes and lower pro-inflammatory signals. Step 4: The net result in explant studies is reduced cytokine output that could otherwise prolong degeneration. The framing stays on repair pathways versus symptom suppression.\\n\\n## How these fit together\\n\\nSingle-compound focus. VIP maps to the immune / autonomic layer. Any broader stack would assign other peptides to separate layers such as direct axon growth or sleep-related recovery. Here","tokens_in":32881,"tokens_out":3494,"cost":0,"prev":"genesis","hash":"8af4ddf9051e797038a0e89f9a5178784114a8a59f67c807ddb4861b375e99b0"},{"ts":"2026-07-17T02:43:25.649Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-neuropathy","response":"22 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8af4ddf9051e797038a0e89f9a5178784114a8a59f67c807ddb4861b375e99b0","hash":"814970a7d9c062b74b764263f77fd08e56991aaaa42527bfcb52ddbba6715174"}]}